Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.59 |
| ▸ | KIF11 | P52732 | 2/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 2/20 | 0.47 |
| ▸ | NGFR | P08138 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31473178 | 1.00 | PARP1 (0.59) | PARP1KIF11CDK4CCND1CA12 | |
| SCHEMBL25791861 | 0.92 | PARP1 (0.55) | PARP1KIF11CDK4CCND1CA12 | |
| SCHEMBL31312450 | 0.92 | PARP1 (0.62) | PARP1KIF11CDK4CCND1CA12 | |
| SCHEMBL5332607 | 0.92 | PARP1 (0.62) | PARP1KIF11CDK4CCND1CA12 | |
| SCHEMBL5342370 | 0.92 | PARP1 (0.58) | PARP1KIF11CDK4CCND1CA12 | |
| SCHEMBL29360002 | 0.87 | GAA (0.67) | PARP1CDK4CCND1CA12CA9 | |
| SCHEMBL354414 | 0.87 | GAA (0.67) | PARP1CDK4CCND1CA12CA9 | |
| SCHEMBL29423967 | 0.87 | GAA (0.67) | PARP1CDK4CCND1CA12CA9 | |
| SCHEMBL6325907 | 0.87 | CDK4 (0.69) | PARP1KIF11CDK4CCND1AR | |
| SCHEMBL30975189 | 0.84 | KIF11 (0.68) | PARP1KIF11CDK4CCND1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| US-7205311-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED | 2007-04-17 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| US-20060111389-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-05-25 | — | — | US | disclosed |
| EP-1363888-A2 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | Cancer Research Technology Limited (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002008193-A2 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111389-A1 | Therapeutic acridone and acridine compounds | TERT, ACIN1, NAT1 | PARP1 118/4885KIF11 2368/4885CDK4 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.